Infectious Diseases Society of America

Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company's Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30th Annual Congress

Retrieved on: 
Tuesday, October 24, 2023
MRI, VAS, CSO, Physical examination, AAV, Osteoarthritis, WOMAC, Clinical trial, Congress, OA, Infectious Diseases Society of America, PALO, Arthralgia, Pain, Inflammation, HIV disease progression rates, Society, Ice, Rest, DSM-IV codes, Disease, Cell, ESGCT, Blood, Disability, Safety, Vasopressin receptor 2, Office of Inspector General, U.S. Department of Health and Human Services, Synovial fluid, Patient, Pharmaceutical industry, Nursing, Vaccine

Study findings noted elevated IL-1Ra expression in synovial fluid and an encouraging trend in symptomatic improvement.

Key Points: 
  • Study findings noted elevated IL-1Ra expression in synovial fluid and an encouraging trend in symptomatic improvement.
  • These data will be delivered in a poster presentation at the European American Society of Gene & Cell Therapy's (ESGCT) 30th Annual Congress being held October 24-27, 2023, in Brussels, Belgium.
  • Clinical trial participants developed various degrees of anti-AAV neutralizing antibodies after injection of GNSC-001, but no capsid targeted T-cell response was detected.
  • The study was supported by funding from the U.S. Department of Defense Peer Reviewed Medical Research Program (PRMRP).

Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023

Retrieved on: 
Tuesday, October 17, 2023
Efficacy, Staphylococcus, Methicillin-resistant Staphylococcus aureus, Ambrose, Abstract, Treatment, Clinical, Circulatory system, MRSA, Biomedical Advanced Research and Development Authority, BARDA, Enterococcus faecalis, Infection, ASPR, MSSA, IDSA, Isolates, Laboratory, Liolios Xirolivaditis, Staphylococcus aureus, PK/PD models, SAB, ABSSSI, CABP, Bronchopneumonia, Administration for Strategic Preparedness and Response, Streptococcus pneumoniae, Prescription Drug User Fee Act, Duke University School of Medicine, Infectious Diseases Society of America, Randomness, Development, Administration, Safety, Patient, PDUFA, HHS, Pharmaceutical industry, Vaccine, Ceftobiprole, Litherland, Enterococcus, Allschwil, Streptococcus, Bloodstream infections

Dr. Marc Engelhardt, Chief Medical Officer of Basilea, stated: “The data presented at IDWeek provide further evidence for the potent antimicrobial activity of ceftobiprole against MRSA and other clinically relevant pathogens.

Key Points: 
  • Dr. Marc Engelhardt, Chief Medical Officer of Basilea, stated: “The data presented at IDWeek provide further evidence for the potent antimicrobial activity of ceftobiprole against MRSA and other clinically relevant pathogens.
  • It also provides results of pharmacokinetic-pharmacodynamic modeling supporting the dosing regimens to treat severe bacterial infections from the successful clinical phase 3 studies.
  • Abstract #1946 – In Vitro Activity of Ceftobiprole against Staphylococcus aureus Bacteremia Isolates from the United States (2018–2020) – L. Duncan, M. Castanheira, J. I.
  • Smart, M. E. Jones, P. G. Ambrose, K. Litherland
    Abstract #2561 – Population Pharmacokinetic Analyses for Ceftobiprole Using Data from Phase 1 and 3 Studies – A. P. Cammarata, K. Litherland, M. C. Safir, S. M. Bhavnani, M. Saulay, J. I.

Iterum Therapeutics to Present Data at IDWeek 2023

Retrieved on: 
Thursday, October 12, 2023
Poster, Therapy, IV, ITRM, Infectious Diseases Society of America, Infection, Pharmaceutical industry

DUBLIN, Ireland and CHICAGO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that three posters will be presented at the Infectious Disease Society of America’s IDWeek 2023 conference taking place in Boston, MA from October 11-15, 2023.

Key Points: 
  • DUBLIN, Ireland and CHICAGO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that three posters will be presented at the Infectious Disease Society of America’s IDWeek 2023 conference taking place in Boston, MA from October 11-15, 2023.
  • Data to be presented at IDWeek 2023 include:
    These Posters will be made available on the Company’s website on the “Publications: Posters & Presentations” page under the “Our Science” tab once the conference ends.

Valneva to Present on Chikungunya at Several Leading Scientific Conferences

Retrieved on: 
Wednesday, October 11, 2023
ISPOR, Vaccine, CDT, Central Time Zone, Tropical medicine, Disease, Donald Mackay Medal, International Society, CHIKV, Pharmacoeconomics, Cost, VLA, Systematic, European Congress of Mathematics, Society, IDSA, Climate, Infectious Diseases Society of America, CEST, Meta-analysis, Vaccination, Pulse vaccination strategy, Pregnancy, Disability-adjusted life year, EDT, Patient, Central European Summer Time, Euronext Paris, Global Burden of Disease Study, Valneva SE, Saint-Herblain, Pharmaceutical industry, Immunodeficiency, Chikungunya, Hygiene

Saint-Herblain (France), October 11, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announces today it will present on the mosquito-borne chikungunya disease at several leading scientific conferences during the fourth quarter of 2023.

Key Points: 
  • Saint-Herblain (France), October 11, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announces today it will present on the mosquito-borne chikungunya disease at several leading scientific conferences during the fourth quarter of 2023.
  • At IDWeek, the annual meeting of the Infectious Diseases Society of America (IDSA), Valneva will support the roundtable discussion “Chikungunya is an Increasing Global Threat: The Need for Better Protection” taking place on October 14, 2023 at 6:00 pm Eastern Daylight Time (EDT) in Boston, Massachusetts.
  • At the American Society of Tropical Medicine and Hygiene (ASTMH) 2023 Annual Meeting in Chicago, Illinois, Valneva will hold two chikungunya presentations on October 20, 2023 at 11:00 am and 12:15 pm Central Daylight Time (CDT).
  • At the International Society of Vaccines Annual Congress taking place in Lausanne, Switzerland Valneva will present on chikungunya on October 24, 2023 at 09:45 am Central European Summer Time (CEST).

AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023

Retrieved on: 
Wednesday, October 11, 2023
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Infection, AN2, Kidney, PK, IDSA, Infectious Diseases Society of America, Alcohol dehydrogenase, Impact, Therapy, NTM, Poster, Mycobacteroides abscessus, MAC, Genotype, ADH, Conference, Tablet, Patient, Pharmaceutical industry, Pharmacokinetics, Safety

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced two oral presentations and three poster presentations at the Infectious Disease Society of America (IDSA) IDWeek 2023 Conference from October 11-15, 2023 in Boston, Massachusetts.

Key Points: 
  • AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced two oral presentations and three poster presentations at the Infectious Disease Society of America (IDSA) IDWeek 2023 Conference from October 11-15, 2023 in Boston, Massachusetts.
  • AN2 Therapeutics is currently enrolling patients in the Phase 3 part of its pivotal Phase 2/3 clinical trial evaluating once-daily, oral epetraborole for treatment-refractory Mycobacterium avium complex (MAC) lung disease.
  • “We are excited to showcase our latest data at IDWeek 2023.
  • These results highlight epetraborole’s potent nonclinical activity against MAC isolates, as well as M. abscessus, another difficult-to-treat NTM pathogen.

Day Zero Diagnostics to Present AI-Based Antimicrobial Susceptibility Testing Predictive Models at ID Week

Retrieved on: 
Tuesday, October 10, 2023
ID, DZD, AST, HAI, Infection, Infectious Diseases Society of America, WGS, ABC, Computational biology, Television, Vaccine

BOSTON, Oct. 10, 2023 /PRNewswire/ -- Day Zero Diagnostics Inc. (DZD), an infectious disease diagnostics company harnessing the power of whole-genome sequencing and AI to combat the rise of antibiotic-resistant infections, announced today that it has been selected to deliver two presentations at the 2023 ID Week conference. ID Week is the premier annual conference organized by the Infectious Disease Society of America and will take place October 11-15 in Boston.

Key Points: 
  • ID Week is the premier annual conference organized by the Infectious Disease Society of America and will take place October 11-15 in Boston.
  • Dr. Miriam Huntley, Chief Technology Officer, will present Keynome® gAST, Day Zero Diagnostics' AI-based algorithm that uses whole genome sequences to predict the antimicrobial susceptibility (AST) of an infection, and discuss how this novel technology will impact the future diagnostics and treatment of infectious disease.
  • In addition to the scientific talks, Day Zero Diagnostics is launching a new commercial service at ID Week under its Day Zero Lab Services brand.
  • This new service expands Day Zero Lab Services commercial offerings and is a complement to epiXact® HAI – DZD's market-leading CLIA-certified healthcare-associated infection (HAI) outbreak assay.

The Inner Circle Acknowledges, J. Hudson Garrett, Jr. as a Pinnacle Life Professional for his contributions to the field of Health Care Administration and Policy

Retrieved on: 
Monday, September 11, 2023
Knowledge, American Hospital Association, Society, Infection, Neurocritical Care Society, Hope End, Inner circle, American College of Physicians, Health, Health administration, Journal, Theodore Levitt, Division, Practitioner, Pandemic, Nurse practitioner, Antimicrobial, American College, National Association, Hum Honorary Lifetime Achievement Award, University, Vascular access, Learning, Infectious Diseases Society of America, COVID-19, Georgia State University, Multimedia, Harvard Business Review, University of Louisville School of Medicine, Endemism, Public health, Control, Allied health professions, Society of Critical Care Medicine, Journal of the American Association of Nurse Practitioners, Above, Patient safety, Emergency medical services, Critical Care Medicine (journal), Nursing, Policy, Physician, Medicine

ATLANTA, Sept. 11, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, J. Hudson Garrett, Jr. is acknowledged as a Pinnacle Life Professional for his contributions to the field of Health Care Administration and Policy.

Key Points: 
  • ATLANTA, Sept. 11, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, J. Hudson Garrett, Jr. is acknowledged as a Pinnacle Life Professional for his contributions to the field of Health Care Administration and Policy.
  • Dr. Garrett Jr. pursued graduate education at Georgia State University where he earned a Ph.D. in Health Care Administration and Policy after earning a Master's degree in Business, Nursing, and Public Health.
  • With more than 22 years of experience in the field, Dr. Garrett Jr. established Community Health Associates in 2005 to bring healthcare professionals lifesaving emergency care and safety training.
  • The primary service the company offers is consulting to the healthcare industry, including providers, leaders, medical device companies, pharmaceutical companies, and others.

PrecisePK Celebrates 30 Years of Bayesian Precision Dosing Partnership With UC San Diego Health, Leading Other UC Hospitals To Follow

Retrieved on: 
Thursday, August 24, 2023
Partnership, Society, Infectious Diseases Society of America, Tacrolimus, Jacobs Medical Center, Rady Children's Hospital, Software, Infection, Survival, Society of Infectious Diseases Pharmacists, Cancer, UC San Diego Health, Pharmacokinetics, Staphylococcus aureus, AKI, Pharmacist, Aminoglycoside, Hospital, Vancomycin, UC, Guideline, Patient, Patient safety, SAN, AUC, Busulfan, Scripps Health, Pharmacology, Safety, American Society of Health-System Pharmacists, Pharmaceutical industry, Generic drug, Medical imaging, List of things named after Thomas Bayes

SAN DIEGO, Aug. 24, 2023 /PRNewswire/ -- Today, PrecisePK announces the celebration of the 30th anniversary of its partnership with UC San Diego Health.

Key Points: 
  • SAN DIEGO, Aug. 24, 2023 /PRNewswire/ -- Today, PrecisePK announces the celebration of the 30th anniversary of its partnership with UC San Diego Health.
  • This decades-long initiative has proven the success of using Bayesian precision dosing to improve patient outcomes.
  • With other UC hospitals joining, PrecisePK is delivering state-of-the-art Bayesian therapeutic drug monitoring technology to a total of 9 prominent sites.
  • PrecisePK and UCSD Health mark 30 years of partnership in vancomycin AUC precision dosing, leading others to follow.

Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases

Retrieved on: 
Tuesday, August 22, 2023
Infectious Diseases Society of America, University, Survival, Infection, Toxicity, LNC, IDSA, Trial of the century, Cryptococcosis, Patient, University of Minnesota Medical School, Fungal infection, MPH, Enactment, NYSE, Pharmaceutical industry, MD

While further clinical trials are needed in other fungal conditions, the EnACT trial establishes proof of concept for the safe and effective treatment of invasive fungal infections.

Key Points: 
  • While further clinical trials are needed in other fungal conditions, the EnACT trial establishes proof of concept for the safe and effective treatment of invasive fungal infections.
  • In this randomized trial of 141 HIV-positive individuals afflicted by life-threatening cryptococcal meningitis, the oral amphotericin MAT2203 product combined with oral flucytosine appears promising for cryptococcal meningitis with antifungal activity, similar survival, and less toxicity than intravenous amphotericin B.
  • The publication of the EnACT data in Clinical Infectious Diseases is yet another milestone for our development program.
  • We would like to thank all the EnACT participants, our dedicated investigators, and the entire clinical study team in Uganda for their commitment to this important clinical trial.”

Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok® Phase 3 Trial

Retrieved on: 
Thursday, August 10, 2023
Infectious Diseases Society of America, MLT, Clinical trial, Minocycline, IDSA, Patient, Control, ITT, Safety, Pharmaceutical industry, Citius, Altius, Fortius

Pending confirmation from an adjudication committee of independent reviewers, the Company believes all 92 events required to complete the trial have been achieved.

Key Points: 
  • Pending confirmation from an adjudication committee of independent reviewers, the Company believes all 92 events required to complete the trial have been achieved.
  • Several patients remain in active treatment, which may result in additional events.
  • "This is a significant milestone for Citius as we approach completion of the Phase 3 Mino-Lok trial.
  • The Mino-Lok Phase 3 pivotal superiority trial ( NCT02901717 ) is a multi-center, randomized, open-label, blinded study to determine the efficacy and safety of Mino-Lok (MLT), a novel antibiotic lock therapy that combines minocycline with edetate disodium.